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Amaia Hervás, and Mònica Guxens
This study aims to estimate the prevalence of autism spectrum disorders (ASD) in 2017 and the ASD diagnosis incidence
between 2009 and 2017 in children living in Catalonia region in Spain, and their temporal and geographical variability. We
used administrative data for all children aged 2–17 years who were insured in the public Catalan Health System between 2009
and 2017.We identified all ASD cases diagnosed between 2009 and 2017 (ICD-9 codes 299.0, 299.1, 299.8, and 299.9). We esti-
mated the ASD prevalence in 2017 and the overall annual incidence between 2009 and 2017, then stratified by sex, age group,
and healthcare area. We used Poisson regression models to assess temporal trends in the incidence and mixed-effects Poisson
regression models to assess geographical variability. We observed an ASD prevalence of 1.23% (95% confidence interval
[CI] 1.21–1.25) in 2017, with 1.95% (95%CI 1.92–1.99) for boys and 0.46% (95%CI 0.44–0.48) for girls, the highest prevalence
being in 11- to 17-year-olds (1.80%, 95%CI 1.76–1.83). The ASD diagnosis incidence increased from 0.07% (95%CI 0.06–0.09)
in 2009 to 0.23% (95%CI 0.21–0.24) in 2017, with a higher increase in girls, and in children aged 2–5 years at the time of diag-
nosis. We only observed geographical differences in prevalence in the 2017 data. We also detected a threefold increase in the
diagnosis incidence overall, which was even more pronounced in girls and at early ages. In conclusion, the ASD prevalence
observed in this study was 1.23% in 2017, with a sex ratio of 4.5 in favor of boys, which is consistent with previous studies.
Autism Res 2019, 12: 1693–1705. © 2019 The Authors. Autism Research published by International Society for Autism Research
published byWiley Periodicals, Inc.
Lay Summary: Autism spectrum disorders (ASD) are currently well known in our society as one of the most common neu-
rodevelopmental disorders during childhood. The results of our study showed that, in 2017 in Catalonia, slightly more than
one in a 100 children had an ASD diagnosis, it was more common in boys than in girls, and also in older children. In addi-
tion, between 2009 and 2017, we observed an increase in the number of new cases diagnosed each year. The data presented
in this study will assist in planning and evaluating the needs of health services in this geographical region.
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Introduction
Autism spectrum disorders (ASD) are a group of neu-
rodevelopmental conditions caused by atypical brain devel-
opment that begins during prenatal or early postnatal life
[Zachor & Curatolo, 2014]. ASDs are commonly character-
ized by impaired social interaction, deficits in social commu-
nication, and restricted, repetitive, and stereotyped behavior
patterns [American Psychiatric Association, 2013]. The symp-
toms are clinically heterogeneous, and some patients are able
to have an independent and fulfilling life with little support,
while others have a more severe form that interferes with
their quality of life [Farley et al., 2009; Hervas, 2016]. Addi-
tionally, individuals with ASD have a very high prevalence of
comorbidities, which could explain the complex, and still
not fully understood, etiology of the disorder [Murray et al.,
2014]. Although considerable effort has been devoted to the
etiological factors of ASD, no single cause has been identified.
The available data suggest that this condition results from
different sets of causal factors, including genetic and environ-
mental risk factors [Huguet, Ey, & Bourgeron, 2013;
Modabbernia, Velthorst, & Reichenberg, 2017].
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ASD are a major public health problem due to the world-
wide increase in their prevalence in recent decades reaching
values of between 0.01% in Oman [Al-Farsi et al., 2011] and
2.64% in South Korea [Kim et al., 2011]. The observed differ-
ences between studies might be due to methodological, cul-
tural, and environmental factors [Hansen, Schendel, &
Parner, 2015; Lyall et al., 2017]. Therefore, it is difficult to
compare estimates of ASD prevalence and incidence from
different studies because they may not have been conducted
homogeneously. ASD epidemiological studies have mainly
been based on registers or on multistage screening
approaches. Most studies have been performed in America
and Europe, whereas less data is available for the Western
Pacific, South East Asia, and Eastern Mediterranean regions
[Chaaya, Saab, Maalouf, & Boustany, 2016; Chinawa et al.,
2017; Davidovitch, Hemo, Manning-Courtney, &
Fombonne, 2013; Dekkers, Groot, Díaz Mosquera, Andrade
Zúñiga, & Delfos, 2015; Elsabbagh et al., 2012; Fombonne,
2009b, 2009a; Fortea Sevilla, Escandell Bermúdez, & Castro
Sánchez, 2013; Hewitt et al., 2016; Hill, Zuckerman, &
Fombonne, 2014; Huang et al., 2014; Idring et al., 2015;
Isaksen, Diseth, Schjølberg, & Skjeldal, 2013; May, Sciberras,
Brignell, & Williams, 2017; Pelly, Vardy, Fernandez,
Newhook, & Chafe, 2015; Poovathinal et al., 2016; Raina
et al., 2017; Rudra et al., 2017; Saemundsen, Magnússon,
Georgsdóttir, Egilsson, & Rafnsson, 2013; Skonieczna-
Żydecka, Gorzkowska, Pierzak-Sominka, & Adler, 2017; Sun
et al., 2015; van Bakel et al., 2015; Zahorodny et al.,
2014]. Studies carried out during the last two decades indi-
cate that North America and Europe have the highest preva-
lences of ASD, with median rates of 0.90% and 0.61%,
respectively. In the Western Pacific, ASD prevalence esti-
mates are slightly lower, with a median rate of 0.50%, while
in South America, Eastern Mediterranean, and South East
Asia, ASD prevalence estimates were much lower, with
median rates not exceeding 0.39%. In Europe, several studies
have been conducted, mostly in Northern countries, and
have used existing registers. However, in Spain, the most
recent studies of ASD were based on a two-phase screening
approach. The first study that used this approach was con-
ducted in the Canary Islands in 2012, and reported an esti-
mated ASD prevalence of 0.61% in toddlers [Fortea Sevilla
et al., 2013]. The other study was conducted in one area of
Catalonia and showed an estimated ASD prevalence of
1.55% in preschool children, and 1.00% in primary school
children [Morales-Hidalgo, Roigé-Castellví, Hernández-
Martínez, Voltas, & Canals, 2018]. Regarding sex differences
in ASD diagnosis, most previous studies have shown a
higher ASD prevalence in boys than in girls, with a median
sex ratio of 4 (boy:girl) [Elsabbagh et al., 2012]. Although
ASD symptoms tend to manifest themselves during early
childhood, [American Psychiatric Association, 2013] some
studies have reported higher ASD prevalence in children
aged 4–9 years [Al-Farsi et al., 2011; Skonieczna-Żydecka
et al., 2017; Yeargin-Allsopp et al., 2003]. Furthermore,
although few studies have assessed ASD incidence, they
have all shown an increased incidence in the last years [Bar-
baresi, Katusic, Colligan, Weaver, & Jacobsen, 2005; Chien,
Lin, Chou, & Chou, 2011; Davidovitch et al., 2013;
Hinkka-Yli-Salomäki et al., 2014; Honda, Shimizu, Misumi,
Niimi, & Ohashi, 1996; Jensen, Steinhausen, & Lauritsen,
2014; Lauritsen, Pedersen, & Mortensen, 2004; Nassar
et al., 2009; Pelly et al., 2015; Plubrukarn, Piyasil,
Moungnoi, Tanprasert, & Chutchawalitsakul, 2005; Powell
et al., 2000; Raz, Weisskopf, Davidovitch, Pinto, & Levine,
2015; Taylor, Jick, & MacLaughlin, 2013; Williams et al.,
2005; Wong & Hui, 2008]. As for prevalence, the incidence
varies notably between countries and regions; the inci-
dence in Europe and North America is approximately
0.15% [Davidovitch et al., 2013; Diallo et al., 2018; Jensen
et al., 2014; Pelly et al., 2015; Raz et al., 2015; Taylor et al.,
2013], while that in South Asia and Western Pacific regions
is ~0.05% [Chien et al., 2011; Plubrukarn et al., 2005; Wil-
liams et al., 2005;Wong &Hui, 2008].
Overall, very few studies have been carried out in South-
ern European countries, particularly in our region, where lit-
tle is known about the age of diagnosis and the distribution
of prevalence and incidence of diagnosis in each sex. These
data are crucial to understanding how ASD diagnosis is
evolving, and to evaluating and planning the needs of the
healthcare system. Therefore, the aim of this epidemiological
study was to assess the prevalence of ASD in 2017, and its
incidence of diagnosis between 2009 and 2017 among the
child population of the Catalonia region in Spain, as well as
their temporal and geographical variability.
Methods
Population and Study Design
We used administrative data for children insured under the
Catalan Public Health Service between 2009 and 2017. In
this cohort, we identified children diagnosed with ASD at
public healthcare centers between 2009 and 2017, and we
defined population-based denominators based on the total
population of children in 2017, and the total population of
children at risk for each year between 2009 and 2017
(described below). Spain’s National Health System provides
universal access to health services for all native and foreign-
born children [García-Armesto, Begoña Abadía-Taira, Durán,
Hernández-Quevedo, & Bernal-Delgado, 2010], regardless of
socioeconomic/financial status or racial/ethnic identification
[García-Altés, Ruiz-Muñoz, Colls, Mias, & Martín Bassols,
2018; Rajmil, 2000]. This study was reviewed and approved
by the Clinical Research Ethics Committee of the Parc de
Salut Mar.
ASD Cases
In Catalonia, all children diagnosed with ASD in a public
healthcare center are registered by the Catalan Health
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Service in the Minimum Basic Data Set register. This popu-
lation register collects information on the patients’ activity
and health morbidity, and is populated using information
provided by four different types of public healthcare cen-
ters: mental health centers, mental health outpatient
clinics, primary care centers, and hospital discharges.
In this study, we included 2- to 17-year-old children
with ASD diagnosed between 2009 and 2017 based on
the following International Classification of Diseases 9th
edition (ICD-9) codes: 299.0 (autistic disorder), 299.1
(childhood disintegrative disorder), 299.8 (other specified
pervasive developmental disorders), and 299.9 (unspecified
pervasive developmental disorder). In the register, ASD
cases might be duplicated when they are registered in dif-
ferent public healthcare centers or by different health pro-
fessionals. For our study, we selected the first entry in the
register as the first ASD diagnosis as children have a
unique identifier in all centers. We excluded ASD cases
registered before the age of 2 because ASD diagnosis
before this age might not be reliable [American Psychiatric
Association, 2013; Charman & Baird, 2002].
The Catalan territory is divided into 29 healthcare areas
based on geographic, socio-economic, and demographic
factors. For each patient, we collected information about
sex, healthcare area where ASD was diagnosed, and age
(at diagnosis and in 2017). Age was stratified in three cat-
egories: 2–5 years, 6–10 years, and 11–17 years.
Population-Based Denominators
We estimated the total population of children in 2017 and
the total population of children at risk for each year between
2009 and 2017, as registered by the Catalan Health Service
through the Central Register of Insured Persons. The total
population of children was defined as the number of 2- to
17-year-olds in 2017, and the total population of children at
risk as the number of 2- to 17-year-olds who were ASD
diagnosed-free but still at risk of being diagnosed of ASD for
each year between 2009 and 2017. For both population-
based denominators, we used the population on 1st of
January of each year. Both population-based denominators
were stratified by sex, age group, and healthcare areas, using
the same category groups as those for the ASD cases.
Statistical Analyses
We calculated the ASD prevalence in 2017 by dividing the
number of 2- to 17-year-olds with an ASD diagnosis in
2017 (numerator) by the total number of 2- to 17-year-olds
in the population in 2017(denominator). The ASD preva-
lence in 2017 was stratified by sex, age group (age in 2017),
and healthcare area. The differences in ASD prevalence
between sexes, age groups, and healthcare areas were esti-
mated using the chi-squared test. We created a map of the
distribution of ASD prevalence by healthcare area.
We calculated the annual ASDdiagnosis incidence between
2009 and 2017 by dividing the number of newly diagnosed
cases of ASD among 2- to 17-year-olds (numerator) by the
total population at-risk 2- to 17-year-olds for each year
(denominator). Annual ASD diagnosis incidence between
2009 and 2017 was stratified by sex, age group (at diagnosis),
and healthcare area. As observations were independent
between years, we used Poisson regression models to assess
the annual trend of the overall ASD diagnosis incidence
between 2009 and 2017, and that for each sex and age group
(at diagnosis).We performedmixed-effects Poisson regression
analysis to assess differences between healthcare areas
according to sex and age group (at diagnosis). The Aran
healthcare area was excluded because the mixed-effects
Poisson regressionmodel did not converge for this area, most
likely due to the low number of ASD cases diagnosed and the
small population size. Finally, we also createdmaps of the dis-
tribution of ASD diagnosis incidence for each year and for
eachhealthcare area.We provide the 95% confidence interval
(95%CI) for all the variables analyzed.
Statistical analyses were performed using STATA (ver-
sion 14.2; Stata Corporation, College Station, TX) and
Open Epi (version 3.01; Dean AG, Sullivan KM, Soe MM),
and the maps were drawn using QGIS (version 3.0.2
Girona; QGIS Development Team).
Results
Characteristics of the Study Population
In 2017, 1,326,666 children aged 2–17 years were insured
under the Catalan Health Service. Boys (51.5%) and girls
(48.5%) were almost equally represented, and with regards
to age groups 2–5 years old were 22.7%, 6–10 years old
31.6%, and 11–17 years old 45.7%. The ratios were similar
for the overall studied population and by sex and age
groups for the other years of study. Out of the total studied
population in 2017, 15,466 had been diagnosed with ASD.
Most ASD cases were in the 6–10 years age group (48.2%)
followed by the 2–5 years (30.3%), and the 11–17 years
groups (21.5%).
ASD Prevalence in 2- to 17-Year-Olds in 2017
We observed an overall ASD prevalence of 1.23% (95% CI
1.21–1.25) in 2017 (Table 1), significantly higher in boys
(1.95%, 95% CI 1.92–1.99) than in girls (0.46%, 95% CI
0.44–0.48, P < 0.001) with 4.5-fold higher prevalence in
boys (12,647 boys vs. 2,819 girls). We also found signifi-
cant differences in ASD prevalence between age groups
according to the patient’s age in 2017 (P < 0.001), with
the highest prevalence in the 11–17 years age group
(1.80%, 95% CI 1.76–1.83) followed by the 6–10 years
(1.18%, 95% CI 1.14–1.21) and the 2–5 years groups
(0.29%, 95% CI 0.26–0.32). Regarding geographical vari-
ability, the ASD prevalence varied significantly between
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healthcare areas in 2017 (P < 0.001), ranging from 0.55%
(95% CI 0.46–0.64) in the Barcelona Sarrià-Sant Gervasi
healthcare area to 1.84% (95% CI 1.71–1.98) in Solsonès-
Bages-Berguedà healthcare area (Fig. 1).
ASD Diagnosis Incidence in 2- to 17-Year-Olds From 2009
to 2017
During the period between 2009 and 2017, there was a
significant increase in the overall ASD diagnosis incidence
from 0.07% (95% CI 0.06–0.09) in 2009 to 0.23% (95% CI
0.21–0.24) in 2017 (Table 1 and Fig. 2A). ASD diagnosis
incidence increased linearly by 15% (95% CI 1.14–1.15)
each year. Remarkably, we observed a greater increase in
diagnosis incidence between 2012 (0.12%) and 2013
(0.16%) than in other years of the study period. When
stratified by sex, we observed a greater increase in ASD
diagnosis incidence in girls (0.02% in 2009 and 0.09% in
2017) than in boys. However, throughout the entire study
period, the ASD diagnosis incidence remained higher in
Figure 1. Autism spectrum disorders prevalence rate (%) among children from 2 to 17 years old in 2017 stratified by healthcare areas
of Catalonia region, Spain. 1: Aran; 2: Alt Pirineu; 3: Lleida; 4: Terres de l’Ebre; 5: Baix Camp–Priorat; 6: Alt Camp–Conca de Barberà; 7:
Tarragonés–Baix Penedès; 8: Anoia; 9: Solsonès–Bages–Berguedà; 10: Osona; 11: Girona Nord; 12: Girona Sud; 13: Vallès Oriental; 14:
Vallès Occidental Est; 15: Vallès Occidental Oest; 16: Baix Llobregat Nord; 17: Alt Penedès–Garraf; 18: Baix Llobregat Centre-Litoral i
L’Hospitalet de Llobregat; 19: Barcelonès Nord i Maresme; 20: Barcelona Ciutat Vella; 21: Barcelona Sant Martí; 22: Barcelona les Corts;
23: Barcelona Sants–Montjuïc; 24: Barcelona Sarrià–Sant Gervasi; 25: Barcelona Eixample; 26: Barcelona Gràcia; 27: Barcelona Horta–
Guinardó; 28: Barcelona Nou Barris; 29: Barcelona Sant Andreu. Abbreviation: ASD, autism spectrum disorders.
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Figure 2. Autism spectrum disorders diagnosis incidence rate (%) among children from 2 to 17 years old between 2009 and 2017
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boys than in girls. In addition, there was a significant
increase in diagnosis incidence between 2012 and 2013 in
boys that was not detected in girls (Table 1 and Fig. 2B).
Regarding the age groups at diagnosis, we observed a
greater increase in ASD diagnosis incidence in 2- to 5-year-
olds (0.05% in 2009 and 0.25% in 2017) than in the other
age groups (Table 1 and Fig. 2C). However, throughout
the entire period between 2009 and 2017, more children
were diagnosed with ASD in the 6–10 years age group than
in the two other age groups at the time of diagnosis. The
age group with the fewest children diagnosed with ASD
was the 11–17 years old group. The mean age of ASD diag-
nosis was estimated to be 8.8 years, and the median was
8 years. When studying ASD diagnosis incidence by
healthcare area, we noted an increase between 2009 and
2017 in all areas, although there was no clear pattern
across healthcare areas (Fig. 3 and Supporting Information
Table S1). During the study period, when taking the ASD
incidence within each healthcare area separately, the inci-
dence varied significantly in most of the healthcare areas
of Catalonia, except in Alt Camp–Conca de Barberà,
Osona, Aran, Barcelona Ciutat Vella, Barcelona les Corts,
Barcelona Sants, Barcelona Eixample, Barcelona Gràcia,
Barcelona Horta, and Barcelona NouBarris. However,
when assessing differences in the annual diagnosis inci-
dence between healthcare areas, no difference across them
was found. Similarly, there were no significant differences
by sex and age group between healthcare areas from 2009
to 2017 (Supporting Information Fig. S1).
Discussion
The present study has assessed the ASD prevalence in
2017 and the ASD diagnosis incidence between 2009 and
2017, as well as their temporal and geographical variabil-
ity, among children aged 2–17 years in Catalonia region
in Spain. The ASD prevalence in 2017 was estimated at
1.23%, with a sex ratio of 4.5 (boy:girl), and with the
highest prevalence observed in 11- to 17-year-olds. The
incidence of new ASD diagnosed cases increased signifi-
cantly between 2009 and 2017, from 0.07% to 0.23%,
with a greater increase in girls and, notably, in those aged
2–5 years at the time of diagnosis. We also observed dif-
ferences in the ASD prevalence between geographical
regions in 2017, but not in the annual diagnosis inci-
dence across the period studied. When stratified by sex
and age group, there were no significant differences
between geographical regions in the annual diagnosis
incidence over the study period.
Prior to 1990, the first studies on ASD prevalence in
children reported a prevalence of 0.05% [Lotter, 1966],
which has since increased dramatically. Studies carried
out between 2000 and 2016 showed a median worldwide
ASD prevalence of 0.70% [Baxter et al., 2015; Elsabbagh
et al., 2012] and a median ASD prevalence of 0.61% in
Europe [Elsabbagh et al., 2012; Fortea Sevilla et al., 2013;
Idring et al., 2015; Saemundsen et al., 2013; Skonieczna-
Żydecka et al., 2017; van Bakel et al., 2015]. Among the
most recent European studies, the highest ASD preva-
lence was found in Spain with an estimate of 1.55%
among preschool children [Morales-Hidalgo et al.,
2018]. In contrast, the lowest ASD prevalence was found
in Poland with an overall estimate of 0.35% among chil-
dren up to 18 years old in 2014 [Skonieczna-Żydecka
et al., 2017]. The methodologies applied in the different
studies differ in case definition, identification, and diag-
nosis, making it difficult to compare studies. Most of the
studies of ASD prevalence include population-based
screening studies, which are based on samples that are
not always representative of the reference population and
would therefore provide biased estimations. Other stud-
ies, particularly those including large populations, have
used different strategies or datasets to define ASD cases,
including parental reports, healthcare provider datasets,
special educational datasets, or national registers. There-
fore, when interpreting and comparing studies on ASD
prevalence it is crucial to keep in mind the limitations
inherent to each study design in order to draw meaning-
ful conclusions.
In our study, the observed sex ratio of 4.5 (boy:girl) is
in agreement with the median ratio of 4.0 reported in
most epidemiological studies of ASD prevalence [Ameri-
can Psychiatric Association, 2013]. Notwithstanding that,
this ratio varies considerably between studies, ranging
from 1.0 [Chaaya et al., 2016] to 15.7 [Baird et al.,
2006]. The causes of the observed male bias in ASD preva-
lence are not completely understood, but may include
genetic factors or differences in detection and diagnosis.
Some studies have demonstrated that girls could be
protected from inherited and de novo genetic risk vari-
ants for ASD [Constantino, Zhang, Frazier, Abbacchi, &
Law, 2010; Sebat et al., 2007]. Others suggest that genes
on the sex chromosomes and sex hormones, particularly
testosterone, may modulate the effects of genetic varia-
tion on the appearance of an autistic phenotype
[Auyeung et al., 2009; Baron-Cohen et al., 2011;
Werling & Geschwind, 2013]. Differences in detection
and diagnosis of ASD might be due to the fact that girls
with ASD show higher social motivation and a greater
capacity for traditional friendships than boys with ASD
[Bargiela, Steward, & Mandy, 2016; Sedgewick, Hill,
Yates, Pickering, & Pellicano, 2016]. Moreover, girls also
score lower on measures of repetitive and stereotyped
behavior, which might lead to an underdiagnosis of ASD
[Rubenstein, Wiggins, & Lee, 2015].
Early diagnosis of ASD is critical, but it is often delayed
until school age. Evidence suggests that interventions to
improve the functioning in ASD children may be more
effective in younger patients, and early treatment
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improves long-term prognosis [Mandell, 2005]. ASD
symptoms are typically recognized during the second
year of life (12–24 months), but the disorder can be diag-
nosed either before 12 months, if developmental symp-
toms are severe, or after 24 months, if symptoms are
more subtle [American Psychiatric Association, 2013]. In
our study, the highest ASD prevalence was observed in
11- to 17-year-olds, with a mean age at diagnosis of
8.8 years, and a median of 8 years. Our findings are con-
sistent with another study conducted in children up to
17 years old in Sweden, which found that the ASD preva-
lence increased with age, with a higher ASD prevalence
among teenagers and a median age at diagnosis of 8 years
[Idring et al., 2015]. However, the results of our study dif-
fer from those of other studies that compared ASD preva-
lence between age groups [Al-Farsi et al., 2011;
Davidovitch et al., 2013; Latif & Williams, 2007; May
et al., 2017; Sheldrick, Maye, & Carter, 2017; Skonieczna-
Żydecka et al., 2017; Yeargin-Allsopp et al., 2003]. Glob-
ally, these studies found that ASD prevalence was higher
among 5- to 9-year-olds, and that the mean age of diag-
nosis was ~5.5 years. In two additional studies, the ASD
prevalence did not differ between age groups [Harrison,
2005; Kogan et al., 2009]. The lower prevalence rates in
younger children in our study could be due to clinicians’
reluctance to label children as having ASD at very young
ages, or a lack of training among health professionals in
diagnosing ASD at early ages. Nevertheless, our temporal
trend data suggest that ASD diagnosis at early ages has
improved over the study period.
We found a significant threefold increase in overall
ASD diagnosis incidence between 2009 and 2017, consis-
tent with trends in other countries [Davidovitch et al.,
2013; Jensen et al., 2014; Nassar et al., 2009; Pelly et al.,
2015; Raz et al., 2015]. This increase could be due to etio-
logic factors, but is most likely related to non-etiologic
factors; changes in the definition of ASD during the
period could explain the observed overall increase in
the incidence of ASD diagnosis. In the last edition of the
Diagnostic and Statistical Manual of mental disorders
(DSM) [American Psychiatric Association, 2013], ASD
included several disorders that were not included in the
previous editions, which would explain that more chil-
dren could be diagnosed as having ASD. Another possible
explanation could be the increasing awareness of ASD in
recent years among parents, teachers, psychiatrists, and
pediatricians. In the region studied, several professional
training actions in diagnostic tools for ASD (Autism Diag-
nostic Interview Revised (ADI-R) and Autism Diagnostic
Observational Schedule [ADOS]) have been addressed to
professionals working in public mental healthcare centers
since 2011. In addition, the Catalan Health Department
implemented a comprehensive plan in some geographical
areas to improve ASD detection, diagnosis, and treatment.
However, the data showed that ASD diagnosis incidence
still increases each year, which means that the diagnostic
stability of ASD has not yet been achieved. Therefore, there
is a need to invest more resources to improve ASD diagno-
sis, especially at early ages.
The main strengths of our study are the design, which is
based on administrative data, and the large sample size
included. It is one of the few studies carried out in South-
ern Europe based on register data including a large annual
number of births (80,000 per year approximately) [Idescat,
2018]. The last studies conducted in Spain based on multi-
stage screening approach have the advantage of detecting
and evaluating the cases of ASD with better precision but
they have the limitation that only a point prevalence rate
can be estimated. In our study, the use of administrative
data has allowed us to estimate the prevalence, temporal
trends of the diagnosis incidence as well as the geographi-
cal variability for both prevalence and incidence. Our study
also included data from a relatively long time period, from
2009 to 2017, allowing a thorough analysis of temporal
trends. Finally, we studied the differences in prevalence
and incidence of ASD diagnosis for each sex, age group,
and across geographical healthcare areas. However, we
acknowledge that the small numbers in the incidence of
ASD diagnosis across geographical healthcare areas might
have limited our capability of detecting differences.
Our study has also some limitations. The main limita-
tion of our study is its retrospective nature: studies based
on registers only capture individuals who accessed the
healthcare service, rather than sampling from the popula-
tion at large. As a result, participants with the studied dis-
order who are not in contact with these services are yet
unidentified and not included as cases, which may lead
to underestimation of ASD diagnosis prevalence and inci-
dence rates. While we recognize these limitations, other
study designs such as the methods of case confirmation
have also important limitations including a low participa-
tion of families in the study that would lead to bias esti-
mations. On the contrary, the use of data registers is less
costly and more time-efficient and may provide a more
complete coverage of a large population. Furthermore,
Spain’s National Health System provides universal access
to health services for all native and foreign-born children
[García-Altés et al., 2018; García-Armesto et al., 2010].
Some people also have health cover from private insurers,
which covers services offered by the public system, as
well as services beyond those offered by the public system
(e.g., elective surgery or dental care). This provides easier
individual direct access to healthcare, more personalized
care, shorter waiting lists, and private rooms in private
hospitals [Fusté, Séculi, Brugulat, Medina, & Juncà, 2005].
Therefore, the double coverage allows the use of public
services and, at the same time, those that are offered by
private insurers according to the user’s preferences and
needs; thus, this private cover supplements the public
system. In Catalonia, the rate of this double cover is
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much higher than in other Spanish regions, estimated to
reach about 25% of the population [Direcció General de
Planificació en Salut, 2016]. The remaining 75% of the
population is covered only by the public health system.
Therefore, we expect to have a low number of ASD diag-
nosed cases not included in our study, which would lead
to a slight underestimation of prevalence and incidence
estimates found in our study. In addition, study design
masked variation in ASD diagnostic practices. As our
study is based on register data, we cannot confirm that
ASD diagnosis assessment has been made in the standard
way for all ASD cases. While some clinicians work within
a multidisciplinary team, others work independently to
make a diagnostic decision. This fact could partly explain
the variability in ASD diagnosis prevalence and incidence
between healthcare areas. Nevertheless, in all the public
mental healthcare centers of Catalonia where the diagno-
sis of ASD could be made, there is at least one profes-
sional specialized in ADI-R and ADOS tools as clinical
guidelines recommended. This fact, however, does not
ensure that the ASD diagnosis would be done using these
diagnostic tools. As an example, the time constraints for
each visit in the public mental healthcare centers can
lead to the health professionals to perform shorter diag-
nosis based on the DSM criteria instead of ADI-R and
ADOS. Additionally, no efforts are made by the data pro-
vider to perform a case validation of the ASD cases
included in the register. For future studies on the epide-
miological monitoring of ASD based on this data, a case
validation study should be done as well as an evaluation
of the completeness of the data. It is also possible that
ASD diagnosis was underestimated if children were first
diagnosed with an attention deficit and hyperactivity dis-
order, which occurs concomitantly in 30% to 50% of
children with ASD [Davis & Kollins, 2012]. Finally, we
only retrieved information on ASD cases from the public
healthcare centers that are under the Catalan Health
Department. We were unable to access data from private
healthcare centers, the Child Development and Early
Care Centers that are under the Catalan Welfare Depart-
ment, and the Psycho-Pedagogical Assessment Teams
that are under the Catalan Educational Department.
However, in Catalonia there is a health program called
“Healthy Childhood” aimed at children aged 0–14 years
old [Direcció General de Salut Pública, 2008]. This pro-
gram is about issues related to childhood health (physical
and psychomotor development, routine immunizations,
locomotor system, genitourinary system, ophthalmology,
otorhinolaryngology, oral health, etc.) and visits to the
pediatrician are scheduled throughout the whole child-
hood. Although it is estimated that a maximum of 25%
of the population has double health coverage [Direcció
General de Planificació en Salut, 2016], it is important to
point out that most of the children insured in the Cata-
lan Health System follow this program. Therefore, we
expect that most of these ASD diagnosed cases would also
had at least one contact with the public healthcare cen-
ters in relation to their ASD diagnosis or for other reasons
and notify the pediatrician about the diagnosis, that is, at
a regular visits within the “Healthy childhood” program,
and that their ASD diagnosis would be registered.
Although the age of diagnosis might not be accurately
registered for these cases, we were able to include them in
the overall ASD estimations. Future studies should focus
on harmonizing and merging the data from all existing
registers to provide a more accurate estimate of ASD diag-
nosis prevalence and incidence.
In conclusion, in Catalonia region, we found an ASD
prevalence of 1.23% in 2017. This prevalence was higher
in boys than in girls (sex ratio 4.5), and was highest in the
11–17 years age group. We also observed a threefold
increase in ASD diagnosis incidence between 2009 and
2017, and that this was more pronounced among girls and
in children aged 2–5 years at the time of diagnosis. We
observed geographical differences in the ASD prevalence in
2017 between healthcare areas, but not for the annual ASD
diagnosis incidence during the period 2009 and 2017. This
study provides new epidemiological information on the
prevalence and incidence of ASD diagnosis in children in
Catalonia region, and is one of the few studies that has
been carried out in the South of Europe. The data collected
here will add to the available information for planning and
evaluating the needs of the healthcare services in Catalonia,
especially those related to early diagnosis and intervention.
Finally, it is also important to point out to the need to
establish improved methods of registering the diagnosis of
ASD to ensure that the health burden of the condition is
accurately measured.
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Table S1. Autism spectrum disorders prevalence rate (%)
in 2017 and ASD diagnosis incidence rates (%) between
2009 and 2017 among children between 2 to 17 years old
by healthcare areas of the Catalonia region, Spain.
Figure S1. Incidence risk ratio of autism spectrum disor-
ders diagnosis incidence over the study period from 2009
to 2017 between healthcare areas of the Catalonia region,
Spain, stratified by sex and age group at diagnosis. (A)
Boys from 2 to 5 years old (B) Boys from 6 to 10 years old
(C) Boys from 11 to 17 years old (D) Girls from 2 to
5 years old (E) Girls from 6 to 10 years old (F) Girls from
11 to 17 years old.
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